AARD
Aardvark Therapeutics, Inc.
$7.60
+2.60 (+52.00%)
At close · Jul 10
Market Cap
$165.80M
Shares
21,816,385
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.60
Open$5.03
Day$5.03–7.92
52W$3.35–17.94
Avg vol 30d343K
Short int528K · 2.4% float · 1.7d
Short vol49%
DataFeb 2025–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−17%
below
Price vs 50-day avg
+59%
above
RSI (14)
74
overbought
MACD trend
Positive
52-week position
29%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+112%
trailing
6-month return
−50%
trailing
YTD return
−42%
this year
Relative strength
−60%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
1 of 79 funds reported for Jun 30 · net +388 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.42% of float · ▼ -42.1% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 1-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
EPS growth
+43%
Y/Y
Free cash flow
$-54.3M
Balance sheet
$47.1M
net cash
Quant / Vol
risk profile
Volatility
121%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
9.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−17%
Bearish
Price vs 50-day avg
+59%
Bullish
RSI (14)
74
Bearish
MACD trend
Positive
Bullish
52-week position
29%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $5 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
1 of 79 funds reported for Jun 30 · net +388 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.42% of float · ▼ -42.1% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $8 · 29%
52-wk high $18
vs 200-day avg -17%
vs 50-day avg +59%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AARD
this stock
Aardvark Therapeutics, Inc.
|
$165.80M | -42.1% | — | — | 2.4% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AARD | +33.3% | +112.2% | -50.5% | +31.9% | -42.1% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +32.0% | +108.1% | -59.6% | +30.8% | -52.8% |